By What Percentage Can Bristol-Myers Squibb’s Revenue & EBITDA Grow In The Next 3 Years?
Bristol-Myers Squibb’s 3 Year Outlook (2015-2018):
- Revenue Growth ~ 16%
- EBITDA Growth ~ 29%
- Should You Pick Bristol Myers Squibb Stock At $45?
- Should You Pick Bristol Myers Squibb Stock After A 30% Fall Last Year And Q4 Beat?
- Is Bristol Myers Squibb Stock Undervalued At $50?
- Will Bristol Myers Squibb Stock Rebound To Its Pre-Inflation Shock Level of $80?
- Which Stock Is A Better Healthcare Pick – Bristol Myers Squibb Or HCA?
- Will Bristol Myers Squibb Stock Rise Post Q1?
Have more questions about Bristol-Myers Squibb? See the links below.
- What’s Bristol-Myers Squibb’s Fundamental Value Based On Expected 2015 Results?
- By What Percentage Did Bristol-Myers Squibb’s Revenue & EBITDA Grow In The Last 5 Years?
- How Has Bristol-Myers Squibb’s Revenue Composition Changed Over The Last 5 Years
- How Much Revenues Can Bristol-Myers Squibb’s Phase 3 Pipeline Add By 2020?
Notes:
See More at Trefis | View Interactive Institutional Research (Powered by Trefis)